CML highlights from EHA 2018 – treatment options in resistant CML patients, the role of IFN- α in the TKI era and treatment free remission

August 2018 - As part of our educational service, we are delighted to present to you three new expert talks that were first presented during the 23rd Congress of the European Hematology Association. These presentations cover different aspects on CML management like treatment options in resistant CML patients, the role of IFN- α in the TKI era and TFR as a potential new treatment goal.

• Treatment options in resistant CML patients
  (Professor Jane Apperley, London)

• Does IFN- α improve outcome of CML in the TKI era?
  (Dr Franck-Emmanuel Nicolini, Paris)

• TFR – a new treatment goal of CP-CML patients?
  (Dr Delphine Réa, Paris)

If you attended the EHA meeting you can log into the EHA Learning Center with your EHA login details and create a free account. This gives you access to all e-posters (clinical / biology & translational research), abstracts (clinical / biology & translational research) and webcasts from the Education Session on CML.